A number of amici weighed in this week on Novartis Pharmaceuticals’ petition to the U.S. Supreme Court asking the Justices to consider whether the U.S. Court of Appeals for the Federal Circuit (CAFC) should have been allowed to vacate the decision of a previous three-judge panel composed of different judges, thus invalidating Novartis’ patent for a dosing regimen for its multiple sclerosis drug, Gilenya. In January of this year, Novartis followed through on its September 2022 promise that it would appeal the CAFC’s June 2022 decision invalidating its U.S. Patent No. 9,187,405 to the Supreme Court, after the CAFC denied its request to rehear the case.
Recent Posts
- Pro Se Applicant Gets USPTO’s 101 Rejection Vacated at CAFC
- Split Third Circuit Upholds Medicare Price Negotiation Program Under Biden IRA
- U.S. Chamber-Led Coalition Joins Voices Telling Commerce to Nix Valuation-Based Patent Fee Proposal
- Trump Order Bars USPTO Patents Employees from POPA Membership But Will Not Yet Affect Telework
- CAFC Upholds Prosecution Laches Ruling Against Gil Hyatt